Acurx Announces All Patients Demonstrated Clinical and Sustained Cure in Ph2A Open-Label Trial of Ibezapolstat for Treatment of C. difficile Infection (CDI)

WHITE PLAINS, N.Y., Nov. 5, 2020 /PRNewswire/ — Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held, clinical-stage biopharmaceutical company developing an entirely new class of antibiotics for difficult-to-treat bacterial infections, announced that all 10 patients (100%) with mild-to-moderate CDI enrolled in this Ph2A open-label clinical trial met the study’s primary and secondary efficacy endpoints following treatment with orally administered ibezapolstat given 450 mg twice daily for 10 days. Continue Reading.